Ollin Launches With $100m, Two Eye Drugs And Plans To Acquire More

Second Asset To Enter Clinic In 2026

 
• By Mandy Jackson
  
Ollin has a drug in Phase Ib and another nearing the clinic, but continues to hunt for additional ophthalmology assets (Shutterstock)

More from Financing

More from Business